Table 1.
Baseline characteristics
| Liraglutide (n=29) | Insulin (n=28) | Pvalue | |
|---|---|---|---|
| Males/females |
12/17 |
14/14 |
0.514 |
| Age (years) |
58.1 ± 12.1 |
63.9 ± 12.2 |
0.080 |
| Duration of diabetes (years) |
16.0 ± 8.3 |
18.5 ± 10.0 |
0.309 |
| Body weight (kg) |
82.0 ± 16.2 |
76.6 ± 15.5 |
0.122 |
| Body mass index (kg/m2) |
31.3 ± 5.3 |
29.1 ± 3.0 |
0.102 |
| HbA1c (%) |
8.5 ± 1.4 |
9.4 ± 1.6 |
0.023 |
| Fasting plasma glucose (mg/dL) |
159.0 ± 49.7 |
156.4 ± 59.2 |
0.655 |
| Fasting C-peptide (mg/dL) |
2.09 ± 0.97 |
1.97 ± 0.24 |
0.267 |
| Low-density lipoprotein-cholesterol (mg/dL) |
113.1 ± 36.5 |
116.6 ± 28.2 |
0.689 |
| High-density lipoprotein-cholesterol (mg/dL) |
44.2 ± 8.1 |
46.1 ± 13.8 |
0.534 |
| Triglycerides (mg/dL) |
149.4 ± 55.2 |
201.2 ± 145.0 |
0.432 |
| Hypertension (%) |
83 |
86 |
0.760 |
| Dyslipidemia (%) |
90 |
86 |
0.650 |
| Previous treatment |
|
|
|
| Biguanide (%) |
38 |
18 |
0.092 |
| Sulfonylurea (%) |
31 |
21 |
0.410 |
| Alpha-glucosidase inhibitor (%) |
17 |
29 |
0.308 |
| Thiazolidinedione (%) |
21 |
14 |
0.525 |
| DPP-IV inhibitor (%) |
10 |
7 |
0.669 |
| Glinide (%) |
3 |
0 |
0.322 |
| Insulin (%) | 55 | 82 | 0.029 |
Data are mean ± SD or number of subjects.